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Neuropsychiatric HIV-1 
infection study: in Kenya 
and Zaire cross-sectional 
phase I and II
MB SEBIT 
SUMMARY
The objective of the study was to determine the preva­
lence and natural history of human immunodeficiency 
virus type 1 (HIV-1) associated psychiatric, neuropsy­
chological and neurological abnormalities. A total of 
408 subjects were recruited in Nairobi and Kinshasa. 
The study consisted of a cross sectional phase and a 
longitudinal follow up.
Assessment was made by a data collection instru­
ment including six modules. The intercentre and 
intracentre reliability in the use of the each module 
have been formally evaluated. The mean global score 
on the Montgomery-Asberg Depression Rating Scale
Department o f Psychiatry 
University o f Zimbabwe '
PO BoxA178, Avondale 
Harare, Zimbabwe
Correspondence and requests for reprints to: 
Dr MB Sebit
was significantly higher in symptomatic seropositive 
individuals than in matched seronegative controls.
In conclusion, these data suggest that the risk of 
subtle cognitive deficits may be increased in 
asymptomatic stages of HIV-1 infection.
INTRODUCTION
The presence of psychological problems in people with 
human immunodeficiency virus type one (HTV-1) in­
fection has been the subject of considerable attention 
recently. According to world wide estimates by the 
World Health Organization (WHO),1 85 pc of adults 
infected with HTV-1 live outside Western industrial­
ized countries. Over 75 pc of infections in adults are 
transmitted through heterosexual intercourse and more 
than 45 pc of infected subjects are women.
Most of the available evidence comes from surveys 
of well educated, mostly White homosexual men2"4, or 
gays and drug users.5 A series of studies has shown an 
increased vulnerability to psychological distress and a 
significant prevalence of psychiatric disorders associ­
ated with HIV-1 infection, ranging from 30 to 63 pc.6,7 
Furthermore, infection with HIV-1 may lead to a num­
ber of neurological complications, one of the most 
important of which is AIDS dementia complex.8
The incidence of HTV-1 dementia is approximately 
seven per 100 patients per year following development 
of AIDS, with up to 20 pcof HIV-1 infected individuals 
receiving adiagnosis of HI V-1 dementia before death.9,10 
However, a recent study has found no significant de­
cline in cognitive functions before AIDS, unless overt 
dementia is present.11
Concerns about generalization of the currently avail­
able information on the psychiatric, as well as the 
neuropsychological and neurological complications of 
HIV-Linfection has prompted the World Health Orga­
nization to implement the cross-cultural venture called 
World Health Organization Neuropsychiatric AIDS 
Study. The project’s objective was to assess the preva­
lence and the natural history of the above mentioned 
complications in these two geographic areas, with 
respect to sex ratio and distribution of HIV-1 in at-risk 
groups.
MATERIALS AND METHODS
Subjects: A total of 408 subjects (n = 203 in Nairobi, 
Kenya and n = 205 in Kinshasa, Zaire) was recruited 
between October 1990 and August 1991, to participate 
in a cross-section (phase land  II) study. The drop outs
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were 12 (5,5 pc) in Kinshasa and 15 (6,9 pc) in Nairobi.
The drop outs did not differ significantly from the other 
subjects with respect to sociodemographic variables.
The Centres for Disease Control (CDC)12 classifica­
tion of HIV progression was used to classify the staging 
of illness among HIV-1 seropositive subjects. Three 
groups were defined, in each centre, for analytic pur­
poses:
1. One hundred and eighteen symptomatic HTV-1 
seropositive persons either had no symptoms 
(CDC stage II) or had persistent generalised 
lymphadenopathy (CDC stage III). It was con­
ventional to regard these groups as asymptomatic 
in the absence of constitutional neurological, or 
AIDS-defining diseases.
2. One hundred and forty symptomatic HIV-1 
seropositive persons with more severe HIV-1 
complications (CDC stage IV). This group in­
cluded those individuals, who hadother diseases, 
such as neurological disease, secondary infec­
tious disease (e.g. tuberculosis), Herpes zoster, 
Kaposi’s sarcoma or other conditions.
3. One hundred and fifty HIV-1 seronegative con­
trols, matched to seropositive persons by sex, age 
(± 5 years), education (± 3 years), and HTV-1 at 
risk group (homosexuals, intravenous drug users 
and blood recipients).
Assessments: The study was approved by the appro­
priate Ethics Committee, and all subjects gave in­
formed consent. Every third subject who was attending 
the outpatient medical unit(s) of Kenyatta National 
Hospital in Nairobi and Mama Yomo Hospital in 
Kinshasa, aged older than 18 years, able to count from 
one to 25 in his or her native language, and able to read ^  
a series of 10 numbers were enrolled for the study. They 
received pre-test counselling, and had blood drawn for ^  
HTV-1 serological tests (enzyme-linked immunosorbant 
assay [ELISA], and confirmed with the Western blot ^  
test).
Twoweeks later, ataretum  visit, testresultsandpost ^  
test counselling were provided. The HIV-1 seropositive ®  
persons and the HIV-1 seronegative individuals, who 
were suitable for matching were definitively enrolled. 00 
In all these subjects a second blood sample was drawn 
(for CD4 and CDg counts and for the VDRL test) and the 01) 
sociodemographic survey module collected informa­
tion on sex, age, education level, present work status, 2. 
language, and HTV-1 at risk group (if any). Medical
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modules of the Comprehensive Instrument for the 
Collection of Neuropsychiatric Data were adminis­
tered. The remaining modules of the instrument were 
applied one month later (based on the design of the 
study).13
The HIV-1 serostatus of recruited subjects was un­
known to the examiners who performed cognitive/ 
neuropsychological, psychiatric, and neurological as­
sessments except the principal investigator. The design 
and rationale of the WHO neuropsychiatric AIDS 
study and its neuropsychological components have 
been described in detail elsewhere.1314 Relevant assess­
ments are briefly summarised below.
Medical assessment: Physicians performed physi­
cal examinations targeted at HIV-related symptoms 
and signs. Subjects who met 1987 CDC criteria for 
AIDS at baseline were included in the study.
Neurological assessment: All neurological exami­
nations were done by neurologists. Each neurological 
sign was coded separately so that individual signs 
could be examined and factor score could be created 
based on individual items. Finally, the neurological 
diagnoses were made according to the WHO15 and the 
American Academy of Neurology (AAN) criteria, 
Minnespolis, Minn.16
Neuropsychological assessment:
1. The neuropsychological battery was adminis­
tered to the subjects. The functional domains 
assessed by this battery are:
(a) motorspeed/finemotorcontrol(TimeGait,Colour 
Trials 1 & 2, the Wechsler Adult Intelligence 
Scale [WAIS]17 Block Design and Digit Symbol, 
Grooved Pegboard,18 and Trail Making A19); 
sustained attention (Colour Trails 1 and 2 and 
Trail Making A;
selective attention (Colour Trails 2 and WAIS 
Digit Symbol);
cognitive flexibility (Colour Trails 2 and WAIS 
Digit symbol);
perceptual-motor analysis (W AIS Block Design); 
verbal memory (WHO/UCLA20 Auditory Verbal 
Learning Test);
visual memory (WHO/UCLA Picture Memory 
and Interference Test;
verbal fluency (Verbal Fluency Test, animals and 
first names21).
An adapted structured interview for the objective 
evaluation of cognitive performance (SID AM)22,
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which incorporates algorithms for the diagnosis 
ofdementia according to the ICD-1023 andDSM- 
HI-R24;
3. A rating scale of performance in activities of 
daily living (ADL).25
Psychiatric assessment: All psychiatric assess­
ments were performed by psychiatrists, using the Com­
posite International Diagnostic Interview [CIDI],26 
which consists of the sections for psychotic, affective 
and anxiety disorders. It was a structured interview that 
incorporated algorithms for psychiatric diagnosis ac­
cording to th e :
(a) International Classification of Diseases, 10th Re­
vision (ICD-10)23, and DSM-IH-R24;
(b) the 18 item version27 of the Brief Psychiatric 
Rating Scale (BPRS)28;
(c) the Montgometery-Asberg Depression Rating 
Scale (MADRS),29 which was administered to 
the subjects.
The laboratory test module collected the results of 
HIV-1 serological tests, CD4 and CD8 counts, VDRL, 
and specific diagnostic tests, as appropriate.
Analysis of the data.
The asym ptom atic and sym ptom atic HIV-1 
seropositive subjects assessed in each centre were 
compared separately with the HIV -1 seronegative con­
trols with respect to the prevalence of psychiatric 
diagnoses according to ICD-10 and DSM-III-R,with 
the mean scores on the individual items of the BPRS 
and the MADRS, and with the mean global scores on 
the same scales. Also, the asymptomatic and symptom­
atic HTV-1 seropositive subjects with HIV-1 sero­
negative controls with respect to the prevalence of 
impairment on individual sections of neurological ex­
amination and the prevalence of current neurological 
diagnoses according to WHO and AAN criteria.
Furthermore, the asymptomatic and symptomatic 
HTV-1 seropositive subjects evaluated in each centre 
were compared separately with HIV-1 seronegative 
controls with respect to the prevalence of impairment 
on individual neuropsychological tests and global 
neuropsychological impairment. Impairment on each 
test was defined as a performance of two or more 
standard deviations worse than the mean of the 
seronegative group. Global impairment was defined as 
an impaired performance on at least three of 10 tests
(impairment on one or both Grooved Pegboard tests or 
on one or both Verbal Fluency tests was counted as one 
impaired test).
Comparisons were made using the Scheffe test for 
continuous measures and the Chi-Squared (X2) test 
(with a Bonferroni correction for multiple testing) for 
categorical measures. Within each centre and each 
serogroup, correlations between global scores on rat­
ing scales and the CD4 count were explored by the 
Pearson Coefficient.
Table I: Sociodemographic characteristics o f subjects.
HIV-1-
A/HIV-1+
S/HIV-1+
Kinshasa 
n*85  
n = 52 
n = 68
Nairobi 
n = 65 
n -66  
n°72
Sax Male pc 
HIV-1- 56,5 pc 75,4 pc
A/HIV-1+ 63,5 pc 63,6 pc
S/HIV-1+ 51,5 pc 66,7 pc
Age (mean±SD) 
HIV-1- 33,9 ±7,8 30,0 ±8,6
A/HIV-1+ 32,3 ±7,6 30,7 ±8,6
S/HIV-1+ 33,8 ±7,6 33,2 ±9,6
Education (mean ± SD) 
HIV-1- 10,8 ±2,4 8,2 ±2,6
A/HIV-1+ 9,6 ±2,4 7,1 ±3,9
S/HIV-1+ 9,9 ±2,7 7,1 ±3,6
HIV-1 at-risk group pc* 
I.V. drugs users 
HIV-1- 0 1,5 pc
A/HIV-1+ 0 0
S/HIV-1+ 0 1,4 pc
Homosexual s/Bisexuals 
HIV-1- 1,2 pc 3,0 pc
A/HIV-1+ 3,8 pc 0
S/HIV-1+ 0 4,2 pc
Blood recepients 
HIV-1- 4,7 pc 1,5 pc
A/HIV-1+ 1,9 pc 6,1 pc
S/HIV-1+ 5,9 pc 6,9 pc
HIV-1 s human immunodeficiency virus type 1.
A/HiV-1+ 2  asymptomatic HIV type 1 seropositive subjects. 
S/HIV-H 2  symptomatic HIV type 1 seropositive subjects. 
HIV-1- 2  HIV type 1 seronegative subjects.
'= some subjects belonging to two at-risk groups counted twice.
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RESULTS
Table I summarises the sociodemographic characteris­
tics of the subjects in the two centres. The samples 
collected in the centres were obviously different as to 
males to females ratio and mean education level, 
whereas, they were very similar with respect to mean 
age. Homosexuals/bisexuals, intravenous (TV) drug 
users, and blood recipients were almost absent in both 
centres.
There were two cases of central nervous system 
opportunistic infections in Kinshasa (both of Crypto- 
coccal meningitis), and none in Nairobi.
Prescribed psychotropic medications were taken by 
very few subjects, with the only exception being ben­
zodiazepines used by a substantial proportion of indi­
viduals in Kinshasa, mainly at low doses, for the
Table II: Background medical and immunological 
information on subjects.
HIV-1- 
A/HIV-1+ .
sywv-i+
Kinshasa 
n -85  
n = 52 
n = 68
Nairobi 
n = 65 
n = 66 
n = 72
Malaria pc 
HIV-1- 97,6 pc 72,3 pc
AIHIV-1+ 96,2 pc 84,8 pc
S/HIV-1+ 98,5 pc 91,5 pc
Benzodiazepine pc
HIV-1- 16,7 pc 0
A/HIV-1+ 17,3 pc 1,5 pc
S/HIV-1+ 33,8 pc 2,9 pc
CD4 count X10*/4
(mean±S.D.)
HIV-1- 1,15 ±0,37 0,86 ±0,43,
A/HIV-1+ 0,55 ±0,27 0,56 ±0,34
syHiv-u 0,28 ±0,27* 0,38± 0,71'
CD4 /CD, ratio 
(mean±S.D.) 
HIV-1- 1,2 ±0,6 1,1 ±0,4
A/HIV-1+ 0,3 ±0,2 0,5 ±0,4
S/HIV-1+ 0,2 ±0,2* 0,4 ±1,0*
‘Significant overall differencea among aerogroupe. 
p <  0,0001 (by analysis of variances).
‘  Significant overall differencea among aerogroupe. 
p < 0,001 (by analysis of variance).
management of sleep disturbances. A previous diagno­
sis of malaria was very frequent in Kinshasa. The 
percentage of patients fulfilling CDC criteria for AIDS, 
within the group of symptomatic HIV-1 seropositive 
subjects, was 41,7 pc in Nairobi and 36,8 pc in Kinshasa 
(Table II).
The overall prevalence of lifetime mental disorders 
was not significantly increased in either symptomatic 
or asymptomatic HIV-1 seropositive subjects, com­
pared with controls, in any centre.
Table IQ shows the mean MADRS global score was 
significantly higher in women than in men among 
symptomatic HIV-1 seropositive subjects who were 
assessed in Kinshasa (p < 0,05). The mean BPRS global 
score and the mean scores on the BPRS items “somatic 
concern”, “anxiety”, and “depressed mood” were sig­
nificantly increased in symptomatic but not in
Table III: Mean scores on the MADRS and prevalence 
o f current mental disorders in Subjects.
HIV-1-
A/HIV-1+
S/HIV-1+
Kinshasa 
n = 85 
n = 52 
n = 68
Nairobi 
n = 65 
n = 66 
n = 72
The mean global scores on 
MADRS
F/M socres 
HIV-1- 2,4 ± 4,9 3,3 ±7,9
A/HIV-1+ 4,3 ± 7,7 5,5 ±9,0
S/HIV-1+ 11,5 ±10,7* 10,1 ±13,4*
ICD-10 Diagnosis pc
Any mental disorders 
HIV-1- 1,2 pc 0
A/HIV-1+ 1,9 pc 4,5 pc
SAilV-1+ 5,9 pc 7,1 pc
DSM-lll-R Diagnosis pc 
Any mental disorders 
HIV-1- 1,2 pc 0
A/HIV-1+ 1,9 pc 4,5 pc
S/HIV-1+ 5,9 pc 6,9 pc
Significant differences (symptomatic seropositive VS 
seronegative subjects): p < 0,01.
MADRS=Mon tgomery-A sberg Depression Scale; F= Females; 
M = Males.
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asymptomatic HTV-1 seropositive subjects, compared 
with those in seronegative controls, in both centres.
Symptomatic HTV-1 seropositive individuals dif­
fered significantly from controls on numerous 
neuropsychological measures (their performance was 
significantly worse on Time Gait, Colour Trails 2, 
WAIS Digit Symbol, Trail Making A, and Verbal 
Fluency, and animals). In Kinshasa and Nairobi the 
prevalence of global neuropsychological impairment 
was significantly higher in low, but not in high educa­
tion, asymptomatic HIV-1 seropositive subjects com­
pared with the corresponding subgroups of HIV-1
CENTRAL AFRICAN
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Table IV: Prevalence o f impairment on individual NP 
tests in subjects.
HIV-1-
A/HIV-1+
S/HIV-1+
Kinshasa 
n = 85 
n = 52 
n = 68
. Nairobi 
n = 65 
n = 66 
n = 72
Impairment on NP Teete 
Time Gait
HIV-1- 4,7 4,6
A/HIV-1+ 5,8 6,0
S/HIV-1+ 
Colour Trail-1
29,4* 22,2*
HIV-1- 3,5 7,7
A/HIV-1+ 7,7 9,0
S/HIV-1+
Performance in ADLs
(mean±S.D.)
16,2* 12.5
HIV-1- 34,2 ±2,0 34,2 ± 4,2
A/HIV-1+ 35,0 ±4,1 34,6 ± 2,5
S/HIV-1+
Education
40,2 ±14,7** 39,2 ±10,1**
Low education subjects, impairment pc
HIV-1- 0 0
A/HIV-1+ 25,0 pc'* 22,7"
S/HIV-1+ 19,0 25,0"
High education subjects, impairment pc
HIV-1- 1,4 pc 5,1 pc
A/HIV-1+ 2,8 pc 0
S/HIV-1+ 19,1' 10,4
*Significant differences (asymptomatic or symptomatic 
seropositive VS seronegative subjects): p < 0,0001. 
fSignificant differences (asymptomatic or symptomatic 
seropositive VS seronegative subjects): p < 0,01.
" Significant differences (symptomatic seropositive VS 
seronegative subjects): p < 0,05.
Vol. 41, No. 10,1995
seronegative individuals. The mostfrequently involved 
tests were Colour Trails 1 (p < 0,05 among symptom­
atic subjects in Nairobi), and Grooved Peg Board, 
dominant (p < 0,01 among symptomatic individuals in 
Kinshasa; and p < 0,05 among asymptomatic subjects 
in Nairobi).
The proportion of symptomatic seropositive sub­
jects presenting at least one subjective cognitive com­
plaint was significantly higher than that of seronegative 
persons in both centres (1,2 pc, p < 0,01 in Kinshasa; 
3,1 pc, p < 0,05 in Nairobi).
Tlie association between the occurrence of at least 
one subjective cognitive complaint and the presence of 
prominent depressive symptoms was significant in 
asymptomatic seropositive subjects enrolled in Kinshasa 
(p < 0,01), and in Nairobi (p < 0,05), and in symptom­
atic seropositive individuals assessed in Kinshasa (p < 
0,01) and in Nairobi (p < 0,05), Table IV. The mean 
total score on the ADL rating scale was significantly 
higher in symptomatic HTV-1 seropositive subjects 
than in controls in the two centres, and it was consis- 
tentlynot increased in asymptomatic HIV-1 seropositive 
subjects (Table IV). No case of dementia according to 
either ICD-10 or D S M -lll-R  was detected in HIV-1 
seronegative and asymptomatic HIV-1 seropositive 
persons in any of the centres.
The prevalence of neurological impairment was 
significantly higher in symptomatic (but not in 
asymptomatic) HIV-1 seropositive individuals, com­
pared with seronegative controls, in the two centres.
Table V: Findings on neurological examination in 
subjects.
HIV-1- .
A/HIV-1+
S/HIV-1+
Kinshasa 
n = 85 
n = 52 
n = 68
Nairobi 
n c 65 
n ■= 66 
n-72
Antisaccadic eye movements
HIV-1- 10,6 18,5
A/HIV-1+ 17,3 22,4
S/HIV-1+ 25,0* 30,6
Frontal lobe release sign 
HIV-1- 1.2 0
A/HIV-1+ 7,7 0
S/HIV-1+ 11,8* 9,7*
*Significant differences (symptomatic seropositive VS 
seronegative subjects): p < 0,05.
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Acute inflammatory demyelinating polyradiculo­
neuropathy was diagnosed according to AAN criteria 
(one case each in Kinshasa andNairobi). No neurologi­
cal diagnosis was made in HIV-1 seronegative sub­
jects.
Comments: Several limitations of the current study 
should be considered. Some potential problems pertain 
to exclusion of the most severe cases of AIDS, which 
are unlikely to be seen in outpatient units.
Also, subjects, who were lacking in the minimum 
arithmetic skills necessary to perform neuropsy­
chological tests, and those who were aged younger than 
18 years (to simplify consent procedures) were ex­
cluded. I
Contrary to many previous studies carried out in this 
research field, the WHO study did not rely on adver­
tisements or contacts with specific communities for 
recruitment2’3,5 (i.e. self-selected a sample of persons). 
Instead subjects were recruited from!the respective 
outpatient clinic(s) where they had come for general 
medical assessment.
The main weakness of the existing studies is that 
they have almost exclusively involved cohorts or cross- 
sections of homosexual men.2'5 Results in this popula­
tion may not generalise to others, however, the WHO 
findings of the present study confirm and allow for 
generalization of results that neuropsychiatric HIV-1 
infection and AIDS have similar complications world­
wide.
In Our symptomatic seropositive subjects the signifi­
cant increase of the MADRS global score wasja consis­
tent finding across the centres, whereas, in the, previous 
study,3 the mean global score on the Hamilton Rating 
Scale for Depression,30 was not significantly increased 
in seropositive subjects, compared with seronegative 
persons. The following explanations of this inconsis­
tency can be proposed:
(a. Thedifferentstructureoftheadoptedratingscales. 
(b. The above mentioned differences in the recruit­
ment procedures.
Subjective cognitive complaints of asymptomatic 
seropositive persons did not correlate significantly to 
the objective neuropsychological performance. This is 
in line with the finding from a previous report by Van 
Gorp etal.3' The non-increased prevalence of dementia 
in the two centres is most likely due to the possible 
earlier onset of HIV-1 related cognitive impairment 
and the more rapid progression of the infection, in fact,
may cause the death of several subjects before they are 
able to reach the most severe stages of cognitive dete­
rioration, as reported elsewhere.32
In sub-Saharan African countries the prevalence of 
dementia among patients with AIDS in Northern Zone 
of Tanzania, figures as high as 54 pc,33 and as low as 3,2 
pc34 in Central Africa can be found in the literature. 
These two African studies’ findings hardly can be 
compared with each other or with those obtained in 
Western countries, owning to huge differences in popu­
lation,sampling procedures and assessment.
Conclusion: On the whole, the results of the psychi­
atric evaluation performance within the cross sectional 
phase of the WHO Neuropsychiatric AIDS Study sug­
gest that the significance of the psychological compli­
cations of symptomatic HTV-1 infection may have 
been under estimated by previous studies carried out on 
self-selected samples of well educated, middle class 
and mostly White homosexual men.
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